{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:56:01Z","timestamp":1790016961785,"version":"4.0.1"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T00:00:00Z","timestamp":1594598400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T00:00:00Z","timestamp":1594598400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Renal fibrosis is a failed regenerative process that facilitates chronic kidney disease progression. The current study was designed to study the effect of erlotinib, a receptor tyrosine kinase inhibitor, on the progression of renal fibrosis. The study included four groups of mice: control group; adenine group: received adenine (0.2% w\/w) daily with food for 4\u00a0weeks; erlotinib group: received 80\u00a0mg\/kg\/day erlotinib orally (6\u00a0ml\/kg\/day, 1.3% w\/v suspension in normal saline 0.9%) for 4\u00a0weeks; adenine\u2009+\u2009erlotinib group: received adenine and erlotinib concurrently. Kidney function and antioxidant biomarkers were measured. Renal expression of Bcl2 and p53 and histopathological changes (tubular injury and renal fibrosis) were scored. Renal tissue levels of transforming growth factor-\u03b2<jats:sub>1<\/jats:sub>, p-ERK1\/2 and p-STAT3 were measured. Results obtained showed significant decrease (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) in serum creatinine, urea and uric acid in erlotinib\u2009+\u2009adenine group. Level of malondialdehyde was decreased significantly (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) while reduced glutathione and catalase levels were increased (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.01) by erlotinib concurrent administration. Erlotinib markedly reduced fibrosis and tubular injury and decreased TGF-\u03b21, p-ERK1\/2 and p-STAT3 (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.5). In addition, expression level of Bcl-2 was elevated (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) while that of p53-was reduced compared to adenine alone. Erlotinib can attenuate renal fibrosis development and progression through anti-fibrotic, antioxidant and anti-apoptotic pathways.<\/jats:p>","DOI":"10.1038\/s41598-020-68480-7","type":"journal-article","created":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T10:04:30Z","timestamp":1594634670000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Erlotinib can halt adenine induced nephrotoxicity in mice through modulating ERK1\/2, STAT3, p53 and apoptotic pathways"],"prefix":"10.1038","volume":"10","author":[{"given":"Ahmed M.","family":"Awad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A.","family":"Saleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nashwa M.","family":"Abu-Elsaad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek M.","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,13]]},"reference":[{"key":"68480_CR1","first-page":"1545","volume":"33","author":"DM Taylor","year":"2018","unstructured":"Taylor, D. M. et al. Health literacy and patient outcomes in chronic kidney disease: a systematic review. Nephrol. Dial. Transplant. 33, 1545\u20131558 (2018).","journal-title":"Nephrol. Dial. Transplant."},{"key":"68480_CR2","first-page":"1","volume":"10","author":"PY Wu","year":"2019","unstructured":"Wu, P. Y., Chao, C. T., Chan, D. C., Huang, J. W. & Hung, K. Y. Contributors, risk associates, and complications of frailty in patients with chronic kidney disease: a scoping review. Ther. Adv. Chronic Dis. 10, 1\u201323 (2019).","journal-title":"Ther. Adv. Chronic Dis."},{"key":"68480_CR3","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1365-2613.2011.00764.x","volume":"92","author":"S Meran","year":"2011","unstructured":"Meran, S. & Steadman, R. Fibroblasts and myofibroblasts in renal fibrosis. Int. J. Exp. Pathol. 92, 158\u2013167 (2011).","journal-title":"Int. J. Exp. Pathol."},{"key":"68480_CR4","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/nrneph.2011.149","volume":"7","author":"Y Liu","year":"2011","unstructured":"Liu, Y. Cellular and molecular mechanisms of renal fibrosis. Nat. Rev. Nephrol. 7, 684 (2011).","journal-title":"Nat. Rev. Nephrol."},{"key":"68480_CR5","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.freeradbiomed.2019.06.012","volume":"141","author":"YY Chen","year":"2019","unstructured":"Chen, Y. Y. et al. Redox signaling in aging kidney and opportunity for therapeutic intervention through natural products. Free Radic. Biol. Med. 141, 141\u2013149 (2019).","journal-title":"Free Radic. Biol. Med."},{"key":"68480_CR6","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1111\/bph.15013","volume":"177","author":"B Corden","year":"2020","unstructured":"Corden, B., Adami, E., Sweeney, M., Schafer, S. & Cook, S. A. IL-11 in cardiac and renal fibrosis: late to the party but a central player. Br. J. Pharmacol. 177, 1695\u20131708 (2020).","journal-title":"Br. J. Pharmacol."},{"key":"68480_CR7","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.cca.2019.01.008","volume":"491","author":"H Zhao","year":"2019","unstructured":"Zhao, H., Ma, S. X., Shang, Y. Q., Zhang, H. Q. & Su, W. microRNAs in chronic kidney disease. Clin. Chim. Acta. 491, 59\u201365 (2019).","journal-title":"Clin. Chim. Acta."},{"key":"68480_CR8","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.bbadis.2012.06.008","volume":"1832","author":"C Beyer","year":"2013","unstructured":"Beyer, C. & Distler, J. H. Tyrosine kinase signaling in fibrotic disorders: translation of basic research to human disease. Biochim. Biophys. Acta Mol. Basis Dis. 1832, 897\u2013904 (2013).","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"68480_CR9","first-page":"764","volume":"9","author":"L Nakopoulou","year":"1994","unstructured":"Nakopoulou, L. et al. Immunohistochemical study of epidermal growth factor receptor (EGFR) in various types of renal injury. Nephrol. Dial. Transplant. 9, 764\u2013769 (1994).","journal-title":"Nephrol. Dial. Transplant."},{"key":"68480_CR10","first-page":"189","volume":"63","author":"K Yoshioka","year":"1990","unstructured":"Yoshioka, K. et al. Identification and localization of epidermal growth factor and its receptor in the human glomerulus. Lab. Invest. 63, 189\u2013196 (1990).","journal-title":"Lab. Invest."},{"key":"68480_CR11","doi-asserted-by":"crossref","first-page":"4407","DOI":"10.1096\/fj.201601359RR","volume":"31","author":"JM Overstreet","year":"2017","unstructured":"Overstreet, J. M. et al. Selective activation of epidermal growth factor receptor in renal proximal tubule induces tubulointerstitial fibrosis. FASEB J. 31, 4407\u20134421 (2017).","journal-title":"FASEB J."},{"key":"68480_CR12","doi-asserted-by":"publisher","first-page":"146154","DOI":"10.1155\/2012\/146154","volume":"2012","author":"AKH Lim","year":"2012","unstructured":"Lim, A. K. H. & Tesch, G. H. Inflammation in diabetic nephropathy. Mediat. Inflamm. 2012, 146154. https:\/\/doi.org\/10.1155\/2012\/146154 (2012).","journal-title":"Mediat. Inflamm."},{"key":"68480_CR13","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1038\/nm.2491","volume":"17","author":"G Boll\u00e9e","year":"2011","unstructured":"Boll\u00e9e, G. et al. Epidermal growth factor receptor promotes glomerular injury and renal failure in rapidly progressive crescentic glomerulonephritis. Nat. Med. 17, 1242\u20131250 (2011).","journal-title":"Nat. Med."},{"key":"68480_CR14","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.ejphar.2016.08.009","volume":"789","author":"M Skibba","year":"2016","unstructured":"Skibba, M. et al. New EGFR inhibitor, 453, prevents renal fibrosis in angiotensin II-stimulated mice. Eur. J. Pharmacol. 789, 421\u2013430 (2016).","journal-title":"Eur. J. Pharmacol."},{"key":"68480_CR15","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.clim.2019.05.014","volume":"205","author":"L Yang","year":"2019","unstructured":"Yang, L. et al. Epidermal growth factor receptor mimotope alleviates renal fibrosis in murine unilateral ureteral obstruction model. Clin. Immunol. 205, 57\u201364 (2019).","journal-title":"Clin. Immunol."},{"key":"68480_CR16","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nrd1612","volume":"4","author":"J Dowell","year":"2005","unstructured":"Dowell, J., Minna, J. D. & Kirkpatrick, P. Erlotinib hydrochloride. Nat. Rev. Drug Discov. 4, 13\u201314 (2005).","journal-title":"Nat. Rev. Drug Discov."},{"key":"68480_CR17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-016-0028-x","volume":"7","author":"C Lis","year":"2017","unstructured":"Lis, C. et al. Development of erasin: a chromone-based STAT3 inhibitor which induces apoptosis in erlotinib-resistant lung cancer cells. Sci. Rep. 7, 1\u201310 (2017).","journal-title":"Sci. Rep."},{"key":"68480_CR18","doi-asserted-by":"publisher","first-page":"18793","DOI":"10.1038\/s41598-019-55208-5","volume":"9","author":"AP Jain","year":"2019","unstructured":"Jain, A. P. et al. MAP2K1 is a potential therapeutic target in erlotinib resistant head and neck squamous cell carcinoma. Sci. Rep. 9, 18793. https:\/\/doi.org\/10.1038\/s41598-019-55208-5 (2019).","journal-title":"Sci. Rep."},{"key":"68480_CR19","doi-asserted-by":"publisher","first-page":"e54738","DOI":"10.1371\/journal.pone.0054738","volume":"8","author":"RN Matar","year":"2013","unstructured":"Matar, R. N., Klein, J. D. & Sands, J. M. Erlotinib preserves renal function and prevents salt retention in doxorubicin treated nephrotic rats. PLoS One 8, e54738. https:\/\/doi.org\/10.1371\/journal.pone.0054738 (2013).","journal-title":"PLoS One"},{"key":"68480_CR20","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1093\/ndt\/gfm393","volume":"22","author":"P Boor","year":"2007","unstructured":"Boor, P., Sebekova, K., Ostendorf, T. & Floege, J. Treatment targets in renal fibrosis. Nephrol. Dial. Transplant. 22, 3391\u20133407 (2007).","journal-title":"Nephrol. Dial. Transplant."},{"key":"68480_CR21","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1093\/ndt\/gfx264","volume":"33","author":"Y Yamamoto","year":"2018","unstructured":"Yamamoto, Y. et al. Erlotinib attenuates the progression of chronic kidney disease in rats with remnant kidney. Nephrol. Dial. Transplant. 33, 598\u2013606 (2018).","journal-title":"Nephrol. Dial. Transplant."},{"key":"68480_CR22","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/nep.13180","volume":"23","author":"V Diwan","year":"2018","unstructured":"Diwan, V., Brown, L. & Gobe, G. C. Adenine-induced chronic kidney disease in rats. Nephrology 23, 5\u201311 (2018).","journal-title":"Nephrology"},{"key":"68480_CR23","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.nefro.2015.08.004","volume":"35","author":"D Claramunt","year":"2015","unstructured":"Claramunt, D., Gil-Pe\u00f1a, H., Fuente, R., Hern\u00e1ndez-Fr\u00edas, O. & Santos, F. Animal models of pediatric chronic kidney disease. Is adenine intake an appropriate model?. Nefrologia 35, 517\u2013722 (2015).","journal-title":"Nefrologia"},{"key":"68480_CR24","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1097\/JTO.0b013e3181d32287","volume":"5","author":"Y Togashi","year":"2010","unstructured":"Togashi, Y. et al. Pharmacokinetics of erlotinib and its active metabolite OSI-420 in patients with non-small cell lung cancer and chronic renal failure who are undergoing hemodialysis. J. Thorac. Oncol. 5, 601\u2013605 (2010).","journal-title":"J. Thorac. Oncol."},{"key":"68480_CR25","doi-asserted-by":"publisher","first-page":"484","DOI":"10.6092\/1590-8577\/3443","volume":"11","author":"KS Gunturu","year":"2010","unstructured":"Gunturu, K. S., Abu-Khalaf, M. & Saif, M. W. Hepatic failure and hepatorenal syndrome secondary to erlotinib: a possible etiology of complications in a patient with pancreatic cancer. JOP 11, 484\u2013485. https:\/\/doi.org\/10.6092\/1590-8577\/3443 (2010).","journal-title":"JOP"},{"key":"68480_CR26","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1186\/s12885-019-5804-0","volume":"19","author":"J Li","year":"2019","unstructured":"Li, J. et al. Computational analysis of receptor tyrosine kinase inhibitors and cancer metabolism: implications for treatment and discovery of potential therapeutic signatures. BMC Cancer 19, 600. https:\/\/doi.org\/10.1186\/s12885-019-5804-0 (2019).","journal-title":"BMC Cancer"},{"key":"68480_CR27","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1158\/1541-7786.MCR-18-1068","volume":"17","author":"C Pham-Danis","year":"2019","unstructured":"Pham-Danis, C. et al. Urea cycle sustains cellular energetics upon EGFR inhibition in EGFR-mutant NSCLC. Mol. Cancer Res. 17, 1351\u20131364 (2019).","journal-title":"Mol. Cancer Res."},{"key":"68480_CR28","first-page":"e1118","volume":"3","author":"LM Mao","year":"2016","unstructured":"Mao, L. M. & Wang, J. Q. Tyrosine phosphorylation of glutamate receptors by non-receptor tyrosine kinases: roles in depression-like behavior. Neurotransmitter (Houst) 3, e1118 (2016).","journal-title":"Neurotransmitter (Houst)"},{"key":"68480_CR29","doi-asserted-by":"crossref","first-page":"11545","DOI":"10.1073\/pnas.97.21.11545","volume":"97","author":"JE Kacharmina","year":"2000","unstructured":"Kacharmina, J. E., Job, C., Crino, P. & Eberwine, J. Stimulation of glutamate receptor protein synthesis and membrane insertion within isolated neuronal dendrites. Proc. Natl. Acad. Sci. USA 97, 11545\u201311550 (2000).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"Suppl 1","key":"68480_CR30","doi-asserted-by":"publisher","first-page":"S62","DOI":"10.21037\/atm.2016.10.64","volume":"4","author":"Y Isaka","year":"2016","unstructured":"Isaka, Y. Epidermal growth factor as a prognostic biomarker in chronic kidney diseases. Ann. Transl. Med. 4(Suppl 1), S62. https:\/\/doi.org\/10.21037\/atm.2016.10.64 (2016).","journal-title":"Ann. Transl. Med."},{"key":"68480_CR31","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.trim.2004.05.001","volume":"13","author":"B Sis","year":"2004","unstructured":"Sis, B. et al. Epidermal growth factor receptor expression in human renal allograft biopsies: an immunohistochemical study. Transpl. Immunol. 13, 229\u2013232 (2004).","journal-title":"Transpl. Immunol."},{"key":"68480_CR32","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1038\/nrneph.2016.91","volume":"12","author":"LR Harskamp","year":"2016","unstructured":"Harskamp, L. R., Gansevoort, R. T., van Goor, H. & Meijer, E. The epidermal growth factor receptor pathway in chronic kidney diseases. Nat. Rev. Nephrol. 12, 496\u2013506 (2016).","journal-title":"Nat. Rev. Nephrol."},{"key":"68480_CR33","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s00467-018-4005-4","volume":"34","author":"K Daenen","year":"2019","unstructured":"Daenen, K. et al. Oxidative stress in chronic kidney disease. Pediatr. Nephrol. 34, 975\u2013991 (2019).","journal-title":"Pediatr. Nephrol."},{"key":"68480_CR34","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.semcdb.2012.05.003","volume":"23","author":"SC Bir","year":"2012","unstructured":"Bir, S. C., Kolluru, G. K., Fang, K. & Kevil, C. G. Redox balance dynamically regulates vascular growth and remodeling. Semin. Cell Dev. Biol. 23, 745\u2013757 (2012).","journal-title":"Semin. Cell Dev. Biol."},{"key":"68480_CR35","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1161\/CIRCRESAHA.111.243972","volume":"110","author":"B Lassegue","year":"2012","unstructured":"Lassegue, B., San Martin, A. & Griendling, K. K. Biochemistry, physiology, and pathophysiology of NADPH oxidases in the cardiovascular system. Circ. Res. 110, 1364\u20131390 (2012).","journal-title":"Circ. Res."},{"key":"68480_CR36","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13046-018-0728-0","volume":"37","author":"MS Weng","year":"2018","unstructured":"Weng, M. S., Chang, J. H., Hung, W. Y., Yang, Y. C. & Chien, M. H. The interplay of reactive oxygen species and the epidermal growth factor receptor in tumor progression and drug resistance. J. Exp. Clin. Cancer Res. 37, 61 (2018).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"68480_CR37","doi-asserted-by":"crossref","first-page":"32655","DOI":"10.18632\/oncotarget.15948","volume":"8","author":"Z Xu","year":"2017","unstructured":"Xu, Z. et al. EGFR inhibition attenuates diabetic nephropathy through decreasing ROS and endoplasmic reticulum stress. Oncotarget 8, 32655\u201332667 (2017).","journal-title":"Oncotarget"},{"key":"68480_CR38","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.3892\/ijmm.2017.2931","volume":"39","author":"Y Ren","year":"2017","unstructured":"Ren, Y. et al. The Sirt1 activator, SRT1720, attenuates renal fibrosis by inhibiting CTGF and oxidative stress. Int. J. Mol. Med. 39, 1317\u20131324 (2017).","journal-title":"Int. J. Mol. Med."},{"key":"68480_CR39","first-page":"479","volume":"12","author":"R Bargi","year":"2017","unstructured":"Bargi, R. et al. Thymoquinone protects the rat kidneys against renal fibrosis. Int. J. Pharm. Sci. Res. 12, 479 (2017).","journal-title":"Int. J. Pharm. Sci. Res."},{"key":"68480_CR40","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s11154-008-9091-3","volume":"9","author":"BS Kasinath","year":"2008","unstructured":"Kasinath, B. S. et al. Novel mechanisms of protein synthesis in diabetic nephropathy\u2014role of mRNA translation. Rev. Endocr. Metab. Disord. 9, 255\u2013266 (2008).","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"68480_CR41","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1681\/ASN.2008111186","volume":"20","author":"W Lieberthal","year":"2009","unstructured":"Lieberthal, W. & Levine, J. S. The role of the mammalian target of rapamycin (mTOR) in renal disease. J. Am. Soc. Nephrol. 20, 2493\u20132502 (2009).","journal-title":"J. Am. Soc. Nephrol."},{"key":"68480_CR42","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1152\/physrev.2001.81.2.807","volume":"81","author":"JM Kyriakis","year":"2001","unstructured":"Kyriakis, J. M. & Avruch, J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol. Rev. 81, 807\u2013869 (2001).","journal-title":"Physiol. Rev."},{"key":"68480_CR43","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1681\/ASN.2004090800","volume":"17","author":"S Omori","year":"2006","unstructured":"Omori, S. et al. Extracellular signal-regulated kinase inhibition slows disease progression in mice with polycystic kidney disease. J. Am. Soc. Nephrol. 17, 1604\u20131614 (2006).","journal-title":"J. Am. Soc. Nephrol."},{"key":"68480_CR44","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1681\/ASN.V112232","volume":"11","author":"D Bokemeyer","year":"2000","unstructured":"Bokemeyer, D. et al. Differential activation of mitogen-activated protein kinases in experimental mesangioproliferative glomerulonephritis. J. Am. Soc. Nephrol. 11, 232\u2013240 (2000).","journal-title":"J. Am. Soc. Nephrol."},{"key":"68480_CR45","doi-asserted-by":"crossref","first-page":"43377","DOI":"10.1074\/jbc.M206373200","volume":"277","author":"G Nowak","year":"2002","unstructured":"Nowak, G. Protein kinase C-and ERK1\/2 mediate mitochondrial dysfunction, decreases in active Na transport, and cisplatin-induced apoptosis in renal cells. J. Biol. Chem. 277, 43377\u201343388 (2002).","journal-title":"J. Biol. Chem."},{"key":"68480_CR46","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/ki.2008.160","volume":"74","author":"AB Rodr\u00edguez-Pe\u00f1a","year":"2008","unstructured":"Rodr\u00edguez-Pe\u00f1a, A. B. et al. Activation of Erk1\/2 and Akt following unilateral ureteral obstruction. Kidney Int. 74, 196\u2013209 (2008).","journal-title":"Kidney Int."},{"key":"68480_CR47","doi-asserted-by":"publisher","first-page":"e111728","DOI":"10.1371\/journal.pone.0111728","volume":"9","author":"Y Wada","year":"2014","unstructured":"Wada, Y. et al. Epidermal growth factor receptor inhibition with erlotinib partially prevents cisplatin-induced nephrotoxicity in rats. PloS one 9, e111728. https:\/\/doi.org\/10.1371\/journal.pone.0111728 (2014).","journal-title":"PloS one"},{"key":"68480_CR48","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1124\/jpet.115.228080","volume":"356","author":"Y Qian","year":"2016","unstructured":"Qian, Y. et al. Novel epidermal growth factor receptor inhibitor attenuates angiotensin II-induced kidney fibrosis. J. Pharmacol. Exp. Ther. 356, 32\u201342 (2016).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"68480_CR49","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1681\/ASN.2004050374","volume":"16","author":"P Hernandez-Vargas","year":"2005","unstructured":"Hernandez-Vargas, P. et al. Suppressors of cytokine signaling regulate angiotensin II-activated Janus kinase-signal transducers and activators of transcription pathway in renal cells. J. Am. Soc. Nephrol. 16, 1673\u20131683 (2005).","journal-title":"J. Am. Soc. Nephrol."},{"key":"68480_CR50","doi-asserted-by":"crossref","first-page":"F1193","DOI":"10.1152\/ajprenal.00419.2010","volume":"300","author":"WN Leonhard","year":"2011","unstructured":"Leonhard, W. N. et al. Curcumin inhibits cystogenesis by simultaneous interference of multiple signaling pathways: in vivo evidence from a Pkd1-deletion model. Am. J. Physiol. Renal Physiol. 300, F1193-1202 (2011).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"68480_CR51","doi-asserted-by":"crossref","first-page":"3422","DOI":"10.4049\/jimmunol.1401779","volume":"194","author":"C Li","year":"2015","unstructured":"Li, C. et al. Noncanonical STAT3 activation regulates excess TGF-beta1 and collagen I expression in muscle of stricturing Crohn\u2019s disease. J. Immunol. 194, 3422\u20133431 (2015).","journal-title":"J. Immunol."},{"key":"68480_CR52","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/ki.2009.98","volume":"76","author":"TC Lu","year":"2009","unstructured":"Lu, T. C. et al. Knockdown of Stat3 activity in vivo prevents diabetic glomerulopathy. Kidney Int. 76, 63\u201371 (2009).","journal-title":"Kidney Int."},{"key":"68480_CR53","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/ki.2010.154","volume":"78","author":"M Pang","year":"2010","unstructured":"Pang, M. et al. A novel STAT3 inhibitor, S3I\u2013201, attenuates renal interstitial fibroblast activation and interstitial fibrosis in obstructive nephropathy. Kidney Int. 78, 257\u2013268 (2010).","journal-title":"Kidney Int."},{"key":"68480_CR54","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1681\/ASN.2011050493","volume":"23","author":"N Liu","year":"2012","unstructured":"Liu, N. et al. Genetic or pharmacologic blockade of EGFR inhibits renal fibrosis. J. Am. Soc. Nephrol. 23, 854\u2013867 (2012).","journal-title":"J. Am. Soc. Nephrol."},{"key":"68480_CR55","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1681\/ASN.2011070645","volume":"23","author":"J Chen","year":"2012","unstructured":"Chen, J. et al. EGFR signaling promotes TGF beta-dependent renal fibrosis. J. Am. Soc. Nephrol. 23, 215\u2013224 (2012).","journal-title":"J. Am. Soc. Nephrol."},{"key":"68480_CR56","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.trsl.2011.06.002","volume":"158","author":"SC Chen","year":"2011","unstructured":"Chen, S. C. et al. Gefitinib attenuates transforming growth factor-beta1-activated mitogen-activated protein kinases and mitogenesis in NRK-49F cells. Transl. Res. 158, 214\u2013224 (2011).","journal-title":"Transl. Res."},{"key":"68480_CR57","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.bbrc.2009.01.147","volume":"380","author":"C Gajate","year":"2009","unstructured":"Gajate, C., Gonzalez-Camacho, F. & Mollinedo, F. Lipid raft connection between extrinsic and intrinsic apoptotic pathways. Biochem. Biophys. Res. Commun. 380, 780\u2013784 (2009).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"68480_CR58","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/s41598-017-00557-2","volume":"7","author":"D Wu","year":"2017","unstructured":"Wu, D. et al. Hydrogen sulfide ameliorates chronic renal failure in rats by inhibiting apoptosis and inflammation through ROS\/MAPK and NF-\u03ba B signaling pathways. Sci. Rep. 7, 455 (2017).","journal-title":"Sci. Rep."},{"key":"68480_CR59","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.pharmthera.2018.10.013","volume":"195","author":"C Tang","year":"2019","unstructured":"Tang, C. et al. P53 in kidney injury and repair: mechanism and therapeutic potentials. Pharmacol Ther. 195, 5\u201312 (2019).","journal-title":"Pharmacol Ther."},{"key":"68480_CR60","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1016\/j.cellsig.2013.07.007","volume":"25","author":"R Samarakoon","year":"2013","unstructured":"Samarakoon, R. et al. Induction of renal fibrotic genes by TGF-\u03b21 requires EGFR activation, p53 and reactive oxygen species. Cell Signal. 25, 2198\u20132209 (2013).","journal-title":"Cell Signal."},{"key":"68480_CR61","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1159\/000443109","volume":"38","author":"A Nemmar","year":"2016","unstructured":"Nemmar, A. et al. Prolonged pulmonary exposure to diesel exhaust particles exacerbates renal oxidative stress, inflammation and DNA damage in mice with adenine-induced chronic renal failure. Cell. Physiol. Biochem. 38, 1703\u20131713 (2016).","journal-title":"Cell. Physiol. Biochem."},{"key":"68480_CR62","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.2337\/db13-1279","volume":"63","author":"MZ Zhang","year":"2014","unstructured":"Zhang, M. Z., Wang, Y., Paueksakon, P. & Harris, R. C. Epidermal growth factor receptor inhibition slows progression of diabetic nephropathy in association with a decrease in endoplasmic reticulum stress and an increase in autophagy. Diabetes 63, 2063\u20132072 (2014).","journal-title":"Diabetes"},{"key":"68480_CR63","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/0003-2697(79)90738-3","volume":"95","author":"H Ohkawa","year":"1979","unstructured":"Ohkawa, H., Ohishi, N. & Yagi, K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem. 95, 351\u2013358 (1979).","journal-title":"Anal. Biochem."},{"key":"68480_CR64","first-page":"273","volume-title":"Methods of enzymatic analysis","author":"HE Aebi","year":"1985","unstructured":"Aebi, H. E. Catalase. In Methods of enzymatic analysis (eds Bergmeyer, H. U. et al.) 273\u2013286 (Verlag Chimie, Weinheim, 1985)."},{"key":"68480_CR65","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3727\/000000008783907008","volume":"17","author":"M Kinomura","year":"2008","unstructured":"Kinomura, M. et al. Amelioration of cisplatin-induced acute renal injury by renal progenitor-like cells derived from the adult rat kidney. Cell Transplant. 17, 143\u2013158 (2008).","journal-title":"Cell Transplant."},{"key":"68480_CR66","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0021-9975(05)80087-8","volume":"112","author":"J Yamate","year":"1995","unstructured":"Yamate, J. et al. Immunohistochemical observations on the kinetics of macrophages and myofibroblasts in rat renal interstitial fibrosis induced by cis-diamminedichloroplatinum. J. Comp. Pathol. 112, 27\u201339 (1995).","journal-title":"J. Comp. Pathol."},{"key":"68480_CR67","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1046\/j.1524-475x.2000.00045.x","volume":"8","author":"CD Kane","year":"2000","unstructured":"Kane, C. D. & Greenhalgh, D. G. Expression and localization of p53 and bcl-2 in healing wounds in diabetic and nondiabetic mice. Wound Repair Regen. 8, 45\u201358 (2000).","journal-title":"Wound Repair Regen."},{"key":"68480_CR68","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1590\/S1676-24442013000100008","volume":"49","author":"AP Percicote","year":"2013","unstructured":"Percicote, A. P. et al. Immunohistochemical expression of p53, BCL-2, BAX and VEGFR1 proteins in nephroblastomas. J. Bras. Patol. Med. Lab. 49, 50\u201356 (2013).","journal-title":"J. Bras. Patol. Med. Lab."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-68480-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-68480-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-68480-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T13:23:51Z","timestamp":1670333031000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-68480-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,13]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["68480"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-68480-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,13]]},"assertion":[{"value":"30 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11524"}}